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Abstract 
Background: Artemisinin and partner drug resistant malaria parasites have emerged in Southeast Asia. If resistance 
were to emerge in Africa it could have a devastating impact on malaria-related morbidity and mortality. This study 
estimates the potential impact of artemisinin and partner drug resistance on disease burden in Africa if it were to 
emerge.
Methods: Using data from Asia and Africa, five possible artemisinin and partner drug resistance scenarios are charac-
terized. An individual-based malaria transmission model is used to estimate the impact of each resistance scenario on 
clinical incidence and parasite prevalence across Africa. Artemisinin resistance is characterized by slow parasite clear-
ance and partner drug resistance is associated with late clinical failure or late parasitological failure.
Results: Scenarios with high levels of recrudescent infections resulted in far greater increases in clinical incidence 
compared to scenarios with high levels of slow parasite clearance. Across Africa, it is estimated that artemisinin and 
partner drug resistance at levels similar to those observed in Oddar Meanchey province in Cambodia could result in 
an additional 78 million cases over a 5 year period, a 7 % increase in cases compared to a scenario with no resistance. 
A scenario with high levels of slow clearance but no recrudescence resulted in an additional 10 million additional 
cases over the same period.
Conclusion: Artemisinin resistance is potentially a more pressing concern than partner drug resistance due to the 
lack of viable alternatives. However, it is predicted that a failing partner drug will result in greater increases in malaria 
cases and morbidity than would be observed from artemisinin resistance only.
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Background
Artemisinin combination therapy (ACT) is the recom-
mended first-line treatment for malaria in Asia and 
Africa. Artemisinin-resistant Plasmodium falciparum 
strains have emerged and spread within South-East Asia 
in recent years [1, 2], resulting in reduced treatment effi-
cacy [3]. Concern has been raised about the potential 
impact on malaria morbidity and mortality if malaria 
parasites with similar levels of artemisinin resistance 
were to spread to or emerge independently in Africa, 
where 90 % of the global mortality from malaria occurs 
[1]. In the past, resistance to two major anti-malarials, 
chloroquine and sulfadoxine–pyrimethamine (SP), arose 
in South-East Asia and spread to Africa, indicating that 
the spread of artemisinin resistance is possible [4]. A 
molecular marker for artemisinin resistant Plasmodium 
falciparum malaria has been identified in Cambodia [5] 
and has subsequently been observed in Vietnam, Thai-
land and Myanmar [6]. Further analyses suggested that 
these artemisinin resistance associated mutations in the 
P. falciparum K-13 propeller gene have mainly resulted 
from independent emergences, rather than a geographi-
cal spread. Evidence of geographic spread between 
Cambodia and Vietnam exists, but there is no evidence 
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of westward spread towards from Cambodia to Myan-
mar [6]. Similarly, there is evidence that K-13 mutations 
observed on the Thai-Cambodia and the Thai-Myanmar 
border have independent evolutionary origins [7].
Currently, few of the mutations associated with arte-
misinin resistance in South East Asia have been iden-
tified in Africa, and those few seen in Africa do not 
appear to be under selection [8, 9]. If artemisinin resist-
ance were to develop in Africa, it is unknown whether 
it would spread from South East Asia or emerge inde-
pendently. Modelling the spread of resistance within 
the continent is very difficult, as it could potentially 
emerge anywhere and in multiple locations. Therefore, 
in this study a simplified approach is adopted whereby 
the potential change in malaria burden is assessed at dif-
ferent fixed levels of artemisinin and partner resistance 
in each endemic country across Africa. Understanding 
the potential impact of resistance is essential for plan-
ning future control options, including the need for non-
artemisinin alternatives for first-line therapy, and to 
quantify the costs and benefits of investing in resistance 
containment. A recent study estimated that widespread 
artemisinin resistance in Africa could result in US$385 
million in productivity losses and US$32 million in addi-
tional medical costs per year [10].
Parasites can become resistant to either the artemisinin 
or the partner drug component of an ACT, or potentially, 
both. In the absence of resistance, the artemisinin deriva-
tive clears the bulk of the parasite biomass but has a very 
short half-life whereas the partner drug has a considera-
bly longer half-life, meaning that it persists in the system 
long enough to clear any remaining parasites. Broadly 
speaking, artemisinin resistance is associated with slow 
parasite clearance (SPC) or early treatment failure (ETF), 
as well as causing recrudescence later after treatment 
[11, 12]. Artemisinin resistance is typically identified by 
monitoring the parasite clearance half-life [11] and pro-
portion of individuals that are parasitaemic 3 days after 
treatment.
Partner drug resistance is more often associated with 
recrudescence around 3–4  weeks after treatment [12]. 
This results in re-emergence of the infection. Thus, iden-
tifying partner drug resistance involves following patients 
up for 28 or 42  days after treatment and regularly test-
ing for parasites using PCR to determine whether the 
appearance of parasites is due to recrudescence or a new 
infection. Late clinical failure (LCF) is defined as clearing 
parasites by day 3, but having signs of severe malaria or 
parasitaemia with a temperature ≥37.5 °C between days 3 
and 28 (or 42). Late parasitological failure (LPF) is defined 
as clearing parasites by day 3 but remaining parasitaemic 
between days 3 and 28 (or 42) and not having LCF.
Here the impact of these two types of resistance on 
malaria incidence and prevalence under scenarios of 
their development or spread in Africa is estimated by 
extending an existing malaria transmission model [13] 
to include the outcomes associated with artemisinin 
and partner drug resistance. Firstly fixed levels of 
resistance are considered under different transmission 
scenarios to explore the potential effects of artemisinin 
and partner drug resistance in terms of increased clini-
cal incidence. Next, data from Cambodia and Africa are 
used to characterize five potential fixed resistance sce-
narios, which are used to estimate how different types 
of resistance could impact clinical incidence and preva-
lence across Africa. Separate resistant parasite popula-
tions are not explicitly modelled, nor are their spread 
over time and space, or any evolution in the degree 
of resistance, given the considerable uncertainty sur-
rounding these issues.
Methods
Model description
A new model of drug resistance is developed within an 
existing age-structured individual-based mathemati-
cal model which describes the full transmission cycle of 
the parasite between humans and mosquitoes, as well as 
disease progression in humans. A brief description of the 
original transmission model is presented in Fig. 1 and full 
details are given elsewhere [14]. The model is extended to 
incorporate the following four ways in which drug resist-
ance could impact on an individual’s treatment outcome 
(full details and model equations are presented in the 
Additional file 1):
1) Slow parasite clearance (SPC)—The proportion of 
the population that are parasitaemic on day 3 after treat-
ment is used as an indicator of slow clearance. Indi-
viduals with SPC are assumed to remain in the treated 
compartment for longer but do eventually clear parasites 
successfully (or to sub-microscopic levels) and progress 
to the prophylactically protected compartment. This out-
come is modelled by tracking an additional state TR with 
an associated longer duration.
2) and 3) Late clinical and parasitological failure (LCF 
and LPF)—It is assumed that individuals with partner-
drug-resistant parasites will recrudesce to either clinical 
(LCF) or asymptomatic (LPF) infection. A recrudescing 
individual initially clears parasites to a sub-microscopic 
level and enters the protected state (P) for a given period 
depending on the drug they have taken. They then move 
to a new state (U2) where they have sub-microscopic 
infection but are no longer protected. Individuals can 
recrudesce from the P or the U2 states to either clinical 
(LCF) or asymptomatic infection (LPF).
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4) Reinfection—It is assumed that a protected indi-
vidual (P) can become infected if challenged with resist-
ant parasites. It is also assumed that an individual with 
partner-drug-resistant parasites can become re-infected 
before the existing infection recrudesces, in which case 
the new infection dominates.
The outcome of early treatment failure is not con-
sidered here—defined as having danger signs of severe 
malaria on days 1–3, having a higher parasite load on day 
2 than day 0, having parasites on day 3 with a tempera-
ture ≥37.5  °C, or parasitaemia on day 3 being ≥25 % of 
the count on day 0—since this type of treatment failure 
is very rarely identified in individuals with artemisinin or 
partner drug resistant parasites. The outcome of severe 
malaria is also not considered, since it is unclear to what 
extent treatment can reduce the risk of an infection 
developing into a severe case, and how this would change 
with drug resistance.
An individual’s existing immunity to malaria will deter-
mine whether their recrudescing infection is either clini-
cal or asymptomatic. It is assumed that a recrudescing 
individual in a high prevalence area has a higher prob-
ability of developing asymptomatic infection rather than 
clinical infection compared to an individual in a low 
prevalence area due to having greater acquired immunity. 
This is important when extrapolating from Cambodia to 
higher prevalence areas in Africa [15].
Generic model simulations
Firstly, the impact of varying levels of LPF, LCF and 
SPC on clinical incidence in five transmission inten-
sity settings (1, 5, 10, 25 and 50 % parasite prevalence in 
2–10 year olds) is investigated to understand which of the 
three outcomes associated with artemisinin and partner 
drug resistance results in the greatest increase in inci-
dence, and how this result is sensitive to the transmission 
intensity. In each simulation, it is assumed that a fixed 
proportion of parasites circulating in a population are 
resistant.
Resistance scenarios and parameter values
Data were collated from three studies in Cambodia and 
two in Africa where varying levels of artemisinin and 
partner drug resistance were found (Table  1). These 
data were used to parameterize five potential resistance 
scenarios.
Scenario 1: Pailin, Cambodia. Based on results of a 
dihydroartemisinin-piperaquine (DHA-PQP) trial con-
ducted in 2008–2010 where there appeared to be resist-
ance against both the artemisinin component and the 
partner drug piperaquine [16] as indicated by SPC and 
recrudescence rates of >10 %. The location represents an 
intermediate resistance scenario.
Scenario 2: Pursat, Cambodia. From the same study as 
scenario 1, day three positives and some recrudescence 
Fig. 1 Malaria transmission model—human dynamics. Susceptible individuals (S) bitten by an infectious mosquito develop either asymptomatic 
infection (A) or clinical disease (T, TR, D) according to their level of immunity. Individuals treated for clinical disease with artemisinin-sensitive 
parasites (T) or artemisinin-resistant parasites (TR) clear infection (at different rates) and move to the prophylactically protected compartment (P) 
before returning to the susceptible compartment. Individuals with partner drug-resistant parasites can recrudesce from either the prophylactically 
protected compartment (P) or the post-treatment sub-patent infection compartment (U2) to clinical disease or asymptomatic infection. Prophylacti-
cally protected individuals can be re-infected, but with a lower probability than those in the fully susceptible state, based on the level of protection 
from the anti-malarial. Super infection can occur for asymptomatic patent (A) and sub-patent (U) infected individuals
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were observed after DHA-PQP treatment in Pursat, but 
at a much lower level than Pailin, although a higher pro-
portion of recrudescing individuals developed clinical 
symptoms compared to scenario 1 [16]. This suggests 
some degree of artemisinin resistance but very low or 
absent piperaquine resistance. This location is used to 
represent a low resistance scenario.
Scenario 3: Oddar Meanchey, Cambodia. In this loca-
tion day three positivity and recrudescence are very high, 
indicating high levels of resistance to artemisinin and 
the partner drug [17]. This is to date one of the highest 
observed treatment failure to an ACT anywhere in the 
world and represents the current worst-case scenario.
Scenario 4: Tasanh, Cambodia. The studies from this 
location used artesunate (AS) monotherapy for 7  days 
[18]. Recrudescence was found to be low, but day-3 
positivity was high. This scenario is used to consider the 
impact of a parasite population resistant to artemisinin, 
but sensitive to the partner drug (with low recrudes-
cence) based on the assumption that SPC would still have 
occurred in the presence of a partner drug.
Scenario 5: Sudan and Uganda. Data from two studies 
are combined to examine the efficacy of artesunate + sul-
fadoxine–pyrimethamine (AS  +  SP) [19, 20]. There is 
no confirmed artemisinin resistance in Africa to date, 
whereas SP resistance is widespread [4]. Therefore this 
example represents a scenario where the artemisinin 
component of the drug is fully effective but the partner 
drug is failing.
Africa model simulations
The potential impact of artemisinin and/or partner drug 
resistance in Africa is estimated by simulating the impact 
of each of the five resistance scenarios. Simulations were 
run at the resolution of the first administrative unit 
across Africa (sub-national regions) [14]. At this spatial 
unit, four data layers were incorporated: (1) underlying 
population demographics [21, 22], (2) parasite prevalence 
in 2010 [23], (3) seasonal patterns of transmission [24], 
and (4) intervention coverage: including access to treat-
ment and LLIN coverage [14, 25–27] (see Additional 
file 1 for details). For each resistance scenario the clinical 
incidence and parasite prevalence (as detected by micros-
copy or RDTs) are simulated for each first administrative 
unit in Africa from 2016 to 2020 and compare it to a sce-
nario with no resistance. For simplicity it is assumed that 
all anti-malarials in use are artemisinin-based combina-
tions which, although not currently the case, is likely to 
reflect future treatment trends. ACT coverage is defined 
as the proportion of symptomatic malaria cases receiving 
an anti-malarial. To simplify simulations, it is assumed 
that resistance to the artemisinin component or part-
ner drug is uniform across Africa as characterized in the 
resistance scenarios, regardless of which ACT regimens 
are used in different parts of Africa. Country-specific 
yearly estimates of LLIN scale-up up to 2012 are incorpo-
rated and it is assumed that coverage remains at the 2012 
levels in future years. Resistance is introduced in 2012, so 
by 2016, the model has reached a new equilibrium.
Results
Generic model simulations
Figure 2, shows the estimated impact of scenarios where 
20 %. 40, 60, 80 or 100 % of infections have one of three 
treatment outcomes: (1) LCF: individuals infected with 
resistant parasites always recrudesce and have a 25  % 
higher probability of recrudescing to clinical disease 
compared to infection with a sensitive parasite (dark blue 
bars), (2) LPF: all individuals infected with resistant para-
sites recrudesce to asymptomatic infection only, without 
clinical symptoms (medium blue bars), and 3) SPC: indi-
viduals with resistant parasites take 50 % longer to clear 
their infection (light blue bars).
Increasing the proportion of infections with resistant 
parasites that result in SPC after treatment has a small 
effect on clinical incidence across all transmission set-
tings. In contrast, by increasing the proportion of infec-
tions with resistant parasites that result in recrudescence 
(either LCF or LPF) a substantial increase in clinical inci-
dence is predicted. This is because LCF/LPF increases 
the days an individual remains infected by up to a few 
months whereas SPC only increases this by a few days. 
In high transmission settings, as expected the increase in 
clinical incidence is much greater when a higher propor-
tion of recrudescing individuals develop clinical disease 
(LCF) rather than asymptomatic infection (LPF). How-
ever, in lower transmission settings, the relative increase 
in incidence resulting from LCF is only slightly greater 
than for LPF.
Africa model simulations
Figure  3 shows geographically-stratified estimates of 
the total increase in all-age clinical incidence per 1000 
individuals over a 5 year period between 2016 and 2020 
compared to a scenario with no artemisinin or partner 
drug resistance over the same time period. The increase 
in clinical incidence due to resistance is predicted to be 
highest where both artemisinin and partner drug resist-
ance is high (Scenario 3). The scenario with high part-
ner drug resistance and no artemisinin resistance (low 
SPC but higher recrudescence) (Scenario 5) has a con-
siderably worse outcome that the scenario with high 
artemisinin resistance (slow parasite clearance and low 
recrudescence) (Scenario 4). This is because individuals 
with recrudescent infections have a much longer infec-
tious period than those with SPC and lead to increased 
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transmission. Also, these individuals can become re-
infected with partner drug resistant parasites during 
the period of prophylaxis that follows treatment with 
an ACT. Although Scenario 2 has lower artemisinin and 
partner drug resistance than Scenario 1, the predicted 
increase in the number of cases is almost as high. This 
is because the probability of developing LCF rather than 
LPF is much higher in Scenario 2 than in Scenario 1. 
This reflects the result shown in Fig. 2 that the impact of 
resistance that gives rise to recrudescence is sensitive to 
the clinical outcome (symptomatic or asymptomatic) of a 
recrudescing individual, especially in a high transmission 
setting.
Table 2 shows the predicted total number of additional 
clinical malaria cases in each country for each resistance 
scenario. The baseline annual incidence per year in the 
absence of resistance is estimated to be approximately 
249 million cases. Scenario 3, which has the highest arte-
misinin and partner drug resistance, results in the most 
severe outcome, with an estimated 78 million additional 
cases of malaria over the 5 year period, an increase of 7 % 
compared to the same 5 year period with no resistance. 
The scenario with high partner drug resistance only (Sce-
nario 5) results in the next worse outcome, with an esti-
mated additional 39 million cases.
The absolute increase in malaria prevalence is pre-
dicted to be small for all resistance scenarios (less than 
2.5 percentage points) (Fig. 4) but shows a different pat-
tern to the increase in clinical incidence. Whilst Sce-
nario 1 was predicted to result in only 8 million more 
malaria cases than Scenario 2, the predicted increase in 
prevalence is much greater in Scenario 1. This is because 
in Scenario 2 a higher proportion of individuals that 
recrudesce are assumed to develop clinical disease and 
are treated, so resistance has less impact on parasite car-
riage. The highest increase in prevalence is estimated 
for Scenario 3 with high artemisinin and partner drug 
resistance.
Fig. 2 Impact of three treatment outcomes of ACT resistance on clinical incidence (mean number of cases of malaria per 1000 individuals per 
year) in five different transmission settings (baseline parasite prevalence in 2–10 year olds = 1, 5, 10, 25 and 50 %). The dark blue bars (LCF) show 
the situation where recrudescing individuals have a 25 % greater probability of developing clinical infection after recrudescing compared to after a 
new infection. The medium blue bars (LPF) show the situation where all recrudescing individuals develop late parasitological failure (asymptomatic 
patent infection). The light blue bars show the situation where individuals clear parasites slowly after treatment but do not go on to recrudesce. The 
proportion of infections recrudescing or with slow parasite clearance is shown on the x-axis
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Discussion
Based on the current levels of artemisinin and partner 
drug resistance observed in Asia and Africa, our results 
suggest that partner drug resistance is likely to result 
in a greater increase in transmission and incidence of 
uncomplicated malaria than artemisinin resistance alone. 
Overall, an additional 39 million cases of malaria are esti-
mated to occur over a 5 year period in Africa if partner 
drug resistance levels were similar everywhere to those 
observed for SP resistance in parts of East Africa, rela-
tive to a scenario with no resistance (a 2.7 % increase in 
overall incidence of uncomplicated malaria). In Cambo-
dia, where current parasite prevalence is very low (~1 % 
[11]), the model suggests an increase in the proportion 
of individuals recrudescing will only result in a small 
increase in clinical incidence. In contrast, in African set-
tings with higher parasite prevalence, partner drug resist-
ance is predicted to have a greater impact on morbidity, 
particularly if the proportion of recrudescing individuals 
developing LCF is high. If ACT resistance in Africa was 
similar to the highest levels of artemisinin and partner 
drug resistance currently observed in Oddar Meanchey 
in Cambodia, it is estimated that there would be 78 mil-
lion additional clinical malaria cases between 2016 and 
2020.
This study highlights the importance of protecting 
the effectiveness of partner drugs in Africa for two rea-
sons. First, partner drug resistance in itself could result 
in higher clinical incidence than artemisinin resistance 
alone. Second, a failing partner drug means that para-
sites surviving the artemisinin phase of ACT treatment 
could be transmitted onwards, potentially increasing the 
prevalence and spread of artemisinin resistance. This has 
implications for investment in drug development, as it 
is important to maintain a pipeline of back-up partner 
drugs as well as investing in potential alternatives for the 
artemisinin derivatives. It also has implications for the 
surveillance of resistance, with monitoring of treatment 
Fig. 3 Absolute increase in clinical malaria incidence per 1000 individuals over 5 years (2016–2020) using five ACT resistance scenarios compared 
to a scenario with no artemisinin or partner drug resistance. All maps were created using the maptools package [30] in R
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Table 2 Malaria cases in 2010, total number of clinical cases of malaria over a 5 year period (2016–2020) for a scenario 
with  no ACT resistance, and  the additional malaria cases for  each resistance scenario over  the same time period (all 
in millions)
Malaria incidence 
in 2010 (millions)
Total malaria cases with no 
ACT resistance (2016–2020) 
(millions)
Additional malaria cases due to ACT resistance (2016–2020) 
(millions)
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5
Angola 7.94 43.76 0.77 0.52 2.19 0.38 1.09
Benin 4.19 28.62 0.26 0.34 0.84 0.00 0.50
Botswana 0.10 0.68 0.05 0.04 0.13 0.02 0.06
Burkina Faso 9.89 54.99 0.34 0.84 0.63 0.00 0.97
Burundi 1.63 5.10 0.22 0.09 0.64 0.13 0.28
Cameroon 10.51 58.64 0.70 0.67 2.03 0.21 1.12
Central Afr Rep 2.37 12.80 0.18 0.17 0.55 0.06 0.29
Chad 5.53 28.49 0.72 0.51 2.02 0.31 1.01
Congo 1.97 10.22 0.24 0.16 0.67 0.10 0.33
Cote d’Ivoire 10.85 57.80 0.65 0.70 2.04 0.18 1.11
Djibouti 0.03 0.13 0.02 0.01 0.05 0.00 0.03
Dem Rep Congo 19.13 128.40 2.34 1.51 7.34 1.06 3.10
Eq. Guinea 0.31 1.97 0.02 0.02 0.07 0.00 0.04
Eritrea 0.35 2.76 0.20 0.07 0.61 0.11 0.28
Ethiopia 2.60 41.38 1.02 0.57 3.25 0.22 1.45
Gabon 0.58 4.64 0.04 0.06 0.16 0.01 0.09
Gambia 0.35 1.85 0.06 0.04 0.18 0.04 0.09
Ghana 8.74 59.20 0.94 0.82 2.90 0.31 1.48
Guinea 5.16 27.27 0.49 0.30 1.48 0.25 0.74
Guinea-Bissau 0.29 2.10 0.07 0.05 0.20 0.04 0.10
Kenya 3.47 23.62 0.53 0.15 2.06 0.12 0.81
Lesotho 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Liberia 1.51 9.59 0.18 0.13 0.54 0.08 0.26
Malawi 6.95 36.22 0.37 0.31 1.14 0.14 0.57
Mali 6.33 48.80 0.32 0.57 0.63 0.00 0.79
Mauritania 0.59 3.12 0.11 0.07 0.33 0.07 0.17
Mozambique 10.31 61.22 0.65 0.71 1.90 0.05 1.14
Namibia 0.21 1.53 0.06 0.03 0.17 0.03 0.07
Niger 5.46 34.27 0.64 0.46 1.86 0.36 1.00
Nigeria 75.33 375.69 7.02 5.04 19.84 2.80 10.12
Rwanda 0.50 1.04 0.10 0.06 0.25 0.04 0.07
Senegal 1.47 8.10 0.23 0.13 0.74 0.07 0.27
Sierra Leone 2.36 9.72 0.21 0.14 0.62 0.09 0.27
Somalia 1.06 5.70 0.42 0.16 1.27 0.20 0.53
South Africa 1.36 4.84 0.51 0.30 1.64 0.20 0.70
South Sudan 3.20 16.69 0.77 0.41 2.13 0.38 1.07
Sudan 6.68 32.64 2.01 0.77 4.90 0.95 2.29
Swaziland 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Tanzania 10.45 41.10 1.22 0.82 3.45 0.56 1.69
Togo 2.82 20.03 0.21 0.27 0.62 0.01 0.36
Uganda 13.26 81.38 1.29 1.04 3.99 0.47 1.98
Zambia 2.51 28.33 0.49 0.25 1.33 0.18 0.63
Zimbabwe 0.99 5.96 0.14 0.05 0.37 0.02 0.13
Totals 249.33 1420.39 26.81 19.30 77.77 10.23 39.04
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outcomes and molecular markers of partner drug resist-
ant parasites in sentinel sites equally as important as 
artemisinin resistance markers.
Although in some of the scenarios considered, partner 
drug resistance has more impact than low levels of arte-
misinin resistance, in such situations it may be possible to 
switch to an alternative and halt or reverse the spread of 
resistance (as has been observed in Tanzania with chlo-
roquine [28]) whereas there are currently no available 
alternatives to artemisinin. This means that if artemisinin 
resistance does appear in Africa, constraining it could 
potentially be much more challenging than addressing 
the issue of partner drug resistance. Alongside the poten-
tial development of resistance to artemisinin combina-
tion therapies in Africa, there are several other threats 
to the significant progress made in reducing malaria 
transmission. These include the spread of resistance to 
insecticides used to treat bed nets and for indoor resid-
ual spraying, the increased ecological suitability of areas 
to support vector populations with climate change, the 
re-introduction of parasites to areas that have achieved 
local elimination, or the waning of financial support from 
major public health organizations.
The impact of partner drug resistance on clinical inci-
dence is sensitive to the parameter determining the 
proportion of recrudescing individuals that develop 
clinical infection versus asymptomatic infection. Studies 
in Cambodia have shown that this parameter can vary 
substantially, with between 20 and 100  % of recrudesc-
ing individuals developing clinical symptoms [16]. How-
ever, all the Cambodia studies were conducted in areas 
of low prevalence (typically ≤1  % [11]) where acquired 
immunity is also likely to be low. In contrast, prevalence 
is currently considerably higher in many parts of Africa, 
meaning individuals are more likely to develop asymp-
tomatic infection. To understand the potential impact of 
ACT resistance in Africa it is important to better under-
stand how higher levels of acquired immunity influence 
Fig. 4 Absolute increase in malaria prevalence resulting from each ACT resistance scenario—comparing prevalence between 2016 and 2020 for 
scenarios with and without resistance
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the probability of whether recrudescence results in LCF 
versus LPF.
The model is parameterised for each first subnational 
administrative unit in Africa to match prevalence, sea-
sonality patterns and treatment and LLIN coverage, 
however, the variation within each spatial unit is not 
captured in this study. Furthermore some areas have a 
greater quantity of data on these variables than others 
and, therefore, in some places there is greater uncertainty 
[23–26]. In this study, fixed static resistance scenarios are 
considered, whereas in reality the development of resist-
ance is a dynamic process and is likely to change rapidly. 
Accurately capturing the development and spread of 
resistance would require models of resistant and sensi-
tive parasite strains and a far greater understanding of 
how these strains interact and the relationship between 
resistant strains and worsening treatment outcomes. 
Further data would be needed to understand how resist-
ance to one component of the ACT increases resistance 
pressures on the other and whether ACT resistance is 
less likely to occur in Africa where there are considerably 
more diverse parasite populations than in Cambodia.
In summary, the results suggest that, given the current 
data on artemisinin and partner drug resistance from 
South East Asia, treatment failure occurring due to resist-
ance to the partner drug is likely to result in substantially 
worse outcomes in an African context compared with 
low levels of artemisinin resistance evidenced only by 
slow parasite clearance rates and low treatment failure 
rates. However, as observed in Cambodia, resistance to 
both components of the ACT may develop side-by-side, 
resulting in the worse outcome than resistance to either 
component alone. Slow parasite clearance alone could still 
result in substantial increases in morbidity and its asso-
ciated mortality in an African context. Close monitoring 
of clinical and parasitological outcomes in sentinel sites in 
Africa, therefore, remains a high priority [29].
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